Anonymous ID: 251b33 Nov. 27, 2021, 8:04 p.m. No.15091873   🗄️.is 🔗kun

>>15091849

Abstract

 

Objective: Ivermectin and sulphadiazine were tested individually to determine their in vitro effects on Toxoplasma gondii grown in human epidermoid larynx carcinoma (Hep-2) cell culture.

 

Study design: In-vitro study.

 

Material and methods: Toxoplasma growth was quantities by an enzyme immunoassay performed directly on the fixed cultures, using a rabbit anti-T. gondii immunoglobulin G as the first antibody and a phosphatase-labeled anti-rabbit immunoglobulin G as the second antibody. For each drug, regression models were used to quantify the relationship between optical density values and antimicrobial agent concentrations in the cultures.

 

Results: The 50% inhibitory concentrations (IC50) of ivermectin and sulphadiazine were found to be 0.2 μg/mL and 7.3 μg/mL after 48 h of exposure, respectively. None of the concentrations tested for each drugs demonstrated toxicity to Hep-2 cells after 72 h of incubation.

 

Conclusion: These results indicate that ivermectin significantly inhibited replication of the tachyzoites of T. gondii RH strain.

 

Keywords: Hep-2; Toxoplasma gondii; in vitro; ivermectin; sulphadiazine.

 

https://pubmed.ncbi.nlm.nih.gov/25207063/